Xiao Xinhua, Shan Huizhuang, Niu Yangyang, Wang Peihong, Li Donghe, Zhang Yuyin, Wang Jiayi, Wu Yingli, Jiang Hua
Department of Hematology and Oncology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangdong, China.
Laboratory Medicine, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Front Mol Biosci. 2022 Apr 26;9:647826. doi: 10.3389/fmolb.2022.647826. eCollection 2022.
TMPRSS2 is a transmembrane serine protease and plays a pivotal role in coronavirus disease 2019 (COVID-19). However, the correlation of TMPRSS2 with prognosis and immune infiltration in tumors has not yet been explored. Here, we analyzed the expression of TMPRSS2 in Oncomine and TIMER databases, the correlation between TMPRSS2 and overall survival in the PrognoScan, Kaplan-Meier plotter, and GEPIA databases. The association between TMPRSS2 and immune infiltration levels was investigated in the TIMER database. In addition, the prognosis of TMPRSS2 related to immune cells in cancers was analyzed. Quantitative real-time PCR (qRT-PCR) confirmed that TMPRSS2 was upregulated in lung adenocarcinoma (LUAD) and downregulated in breast invasive carcinoma (BRCA). We demonstrated that high TMPRSS2 expression was associated with favorable prognosis in LUAD, but it was associated with poor prognosis in BRCA. Interestingly, we found that TMPRSS2 expression was significantly correlated with immune infiltration of B cells, CD4 T cells, macrophages, and dendritic cells in LUAD, and it was positively correlated with the infiltrating levels of CD8 T cells, CD4 T cells, neutrophils, and dendric cells in BRCA. Consistent with the prognosis of TMPRSS2 in LUAD and BRCA, the high expression level of TMPRSS2 has a favorable prognosis in enriched immune cells such as B cells, macrophages, and CD4 T cells in LUAD, and it has a poor prognosis in CD4 T cells and CD8 T cells in BRCA. In conclusion, our results indicate that the prognosis of TMPRSS2 in LUAD and BRCA is significantly correlated with immune cells infiltration. Our study comprehensively revealed the relationship between the prognosis of TMPRSS2 in pan-cancers and tumor immunity.
跨膜丝氨酸蛋白酶2（TMPRSS2）是一种跨膜丝氨酸蛋白酶，在2019冠状病毒病（COVID-19）中起关键作用。然而，TMPRSS2与肿瘤预后及免疫浸润的相关性尚未得到探讨。在此，我们分析了Oncomine和TIMER数据库中TMPRSS2的表达，以及PrognoScan、Kaplan-Meier plotter和GEPIA数据库中TMPRSS2与总生存期的相关性。在TIMER数据库中研究了TMPRSS2与免疫浸润水平的关联。此外，分析了癌症中与免疫细胞相关的TMPRSS2的预后。定量实时聚合酶链反应（qRT-PCR）证实，TMPRSS2在肺腺癌（LUAD）中上调，而在乳腺浸润性癌（BRCA）中下调。我们证明，TMPRSS2高表达与LUAD的良好预后相关，但与BRCA的不良预后相关。有趣的是，我们发现TMPRSS2表达与LUAD中B细胞、CD4 T细胞、巨噬细胞和树突状细胞的免疫浸润显著相关，而与BRCA中CD8 T细胞、CD4 T细胞、中性粒细胞和树突状细胞的浸润水平呈正相关。与LUAD和BRCA中TMPRSS2的预后一致，TMPRSS2的高表达水平在LUAD中对富集的免疫细胞如B细胞、巨噬细胞和CD4 T细胞有良好的预后，而在BRCA中对CD4 T细胞和CD8 T细胞有不良预后。总之，我们的结果表明，TMPRSS2在LUAD和BRCA中的预后与免疫细胞浸润显著相关。我们的研究全面揭示了泛癌中TMPRSS2的预后与肿瘤免疫之间的关系。
